A Phase IIa, randomized, double-blind, placebo-controlled, exploratory
A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis
What was tested
Treatment tested
- DC-TAB
What it measured
Main measures
Safety parameters
Safety
Other measures (1)
Effect endpoints
Papers
Loading reviews and guidelines…
History
- In scope changed from true to false
Started
Apr 2012
Assembled by software from public sources.